PROF. DR. DENIZ TURALSIK SORULAN SORULAR

Prof. Dr. Deniz Tural, M.D

Yazar Deniz Tural 891 0

 

Doç. Dr. Deniz Tural

Bakirköy Eğitim ve Araştırma Hastanesi- Tibbi Onkoloji Kliniği / Bakirköy-İstanbul

 

Tel: + 90 212 414 71 71 e-mail: deniztural@gmail.com

 

Eğitim

  • Cerrahpaşa Tıp Fakültesi, İstanbul üniversitesi                                1996-2002

–Tıp fakültesi öğrenci

 

  • Şişli Eğitim ve Araştırma , İstanbul                                                     2003-2009

–İç hasatlıkları  uzamanlık eğitimi

 

  • Cerrahpaşa Tıp Fakültesi, İstanbul üniversitesi   2010-2013

 

–Medikal onkoloji yandal eğitimi

 

 Meslek Deneyim

  • Akdeniz Üniversitesi Tıp Fakültesi, Antalya                                        2013-2014

-Medikal onkoloji

 

  • Bakirköy Eğitim ve Araştırma Hastanesi, İstanbul           2015-devam

Medical Onkoloji

 

 

Araştırma ve Yayınlar

  1. Tural D, Batur S, Erdamar S, Akar E, Kepil N, Mandel NM, Serdengeçti S. Analysis of PTEN, BRAF and PI3K status for determinationof benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS. Tumour Biol. 2014 ;35 :1041-9.

 

  1. Tural D, Yildiz O, Elcin O, Erdamar S, Guney S, Demireli F, Buyukunal E, Serdengecti S. What is the optimal treatment in clinical stage T3N0M0 rectal cancer?. J BUON. 2014; 19:97-102.

 

 

  1. Tural D, Selcukbiricik F, Özturk MA, Yildiz O, Turna H, Erdamar S, Büyükünal E, Serdengeçti S.The relation between pathological complete response and clinical outcome in patients with rectal cancer. 2013 ;60:1365-70.

 

  1. Tural D, Selcukbiricik F, Erdamar S, Ozkurt CU, Yanmaz T, Mandel NM, Serdengeçti S. Association KRAS G13D tumor mutated outcome in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab. 2013 ;60:1035-40.

 

  1. Akar E, Tural D, Arslan D, Başsorgun Cİ, Yıldız Ö. Late relapse of testicular cancer: Recurrence after 24 years and treatment with chemotherapy alone. J Cancer Res Ther. 2015 Jul-Sep;11(3):661.
  2. Yildiz I, Ekenel M, Akman T, Kocar M, Uysal M, Kanitez M, Varol U, Bayoglu IV, Tural D, Kaplan MA, Avci N, Sürmeli Z, Dede I, Ulaş A, Yazici O, Basaran .Sunitinib for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Turkish Oncology Group Trial. Anticancer Res. 2014;34:4329-34.

 

  1. Gunduz S, Mutlu H, Tural D, Yıldız Ö, Uysal M, Coskun HS, Bozcuk H. Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer. Asia Pac J Clin Oncol. 2015 Dec;11(4):288-92.

 

 

  1. Tural D, Serdengecti S, Demirelli F, Oztürk T, Ilvan S, Turna H, Ozgüroglu M, Büyükünal E. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Br J Cancer. 2014;110:1968-76.

 

9.      Mutlu H, Gündüz S, Büyükçelik A, Yıldız O, Uysal M, Tural D, Bozcuk H, Coşkun HS. The Necessity of Cytoreductive Nephrectomy in Patients With             Metastatic Renal Cell Carcinoma Using Antiangiogenic Targeted Therapy After Interferon Alfa-2b. Clin Genitourin Cancer. 2014 Jun 8. pii: S1558-                       767300109-8.

 

  1. Tural D, Elicin O, Batur S, Arslan D, Oz B, Serdengecti S, Uzel O. Increase in the rate of HPV positive oropharyngeal cancers during 1996-2011 in a case study in Turkey. Asian Pac J Cancer Prev. 2013;14:6065-8.

 

  1. Tural D, Ozturk M, Selcukbiricik F, Yildiz O, Elicin O, Turna H, Guney S, Ozguroglu M. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer. J BUON. 2013;18:385-90.

 

  1. Tural D, Selcukbiricik F, Yıldız O, Elcin O, Erdamar S, Güney S, Demireli F, Büyükünal E, Serdengeçti S. Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer. Int J Clin Oncol. 2014; 19 :889-96.

 

 

  1. Selcukbiricik F, Tural D, Bilici A, Kocak Uzel E, Ozguroglu M, Demirelli F, Buyukunal E, Serdengeçti S. Clinicopathological Features and Localization of gastric cancers and their effects on survival in Turkey. Asian Pac J Cancer Prev. 2013;14:553-6.

 

  1. Selcukbiricik F, Buyukunal E, Tural D, Ozguroglu M, Demirelli F, Serdengecti S. Clinicopathological features and outcomes of patients with gastric cancer: a single-center experience. World J Gastroenterol. 2013;19:2154-61.

 

 

  1. Tural D, Selçukbiricik F, Akar E, Serdengeçti S, Büyükünal E. Gastric cancer: a case study in Turkey. J Cancer Res Ther. 2013;9:644-8

 

  1. Tural D, Eliçin O, Batur S, Arslan D, Öz B, Serdengeçti S, Uzel Ö. Human papillomavirus is independent prognostic factor on outcome of oropharyngeal squamous cell carcinoma. Tumour Biol. 2013;34:3363-9.

 

 

  1. Selcukbiricik F, Tural D, Erdamar S, Buyukunal E, Demirelli F, Serdengecti S. Is Helicobacter pylori a poor prognostic factor for HER-2 SISH positive gastric cancer? Asian Pac J Cancer Prev. 2013;14:3319-22.

 

  1. Selcukbiricik F, Tural D, Aydogan F, Bese N, Büyükünal E, Serdengeçti S. Male breast cancer: 37-year data study at a single experience center in Turkey. J Breast Cancer. 2013;16:60-5.

 

 

  1. Tural D, Selçukbiricik F, Serdengeçti S, Büyükünal E. A comparison of patient characteristics, prognosis, treatment modalities, and survival according to age group in gastric cancer patients. World J Surg Oncol. 2012;10:234.

 

  1. Tural D, Selçukbiricik F, Aydogan F, Bese N, Yetmen O, Ilvan S, Büyükünal E, Serdengeçti S. Male breast cancers behave differently in elderly patients. Jpn J Clin Oncol. 2013 ;4:22-7.

 

  1. Selçukbiricik F, Tural D, Büyükünal E, Serdengeçti S. Perineural invasion independent prognostic factors in patients with gastric cancer undergoing curative resection. Asian Pac J Cancer Prev. 2012;13:3149-52.

 

 

  1. Selçukbiricik F, Tural D, Elicin O, Berk S, Ozgüroglu M, Bese N, Ferhanoglu B. Primary gastric lymphoma: conservative treatment modality is not inferior to surgery for early-stage disease. ISRN Oncol. 2012;2012:951816.

 

  1. Tural D, Yildiz O, Selcukbiricik F, Ozturk MA, Keles Y, Oz B, Uzel O, Demir G, Mandel NM. Olfactory neuroblastomas: an experience of 24 years. ISRN Oncol. 2011;2011:451086.

 

 

  1. Arslan D, Tural D, Akar E. Herbal administration and interaction of cancer treatment. Journal of palliative medicine. J Palliat Med. 2013;16:1466-76.

 

  1. Tural D, Molinas Mandel N, Dervisoglu S, Oner Dincbas F, Koca S, Colpan Oksuz D, Kantarci F, Turna H, Selcukbiricik F, Hiz M. Extraskeletal Ewing’s sarcoma family of tumors in adults: prognostic factors and clinical outcome. Jpn J Clin Oncol. 2012;42:420-6.

 

  1. Tural D, Kilickap S. Is taxane-cisplatin-fluorouracil superior to cisplatin-fluorouracil as induction chemotherapy in outcome in locally advanced head and neck cancers?. J Clin Oncol. 2014;32:259.

 

  1. Arslan D, Tural D, Tatlı AM, Akar E, Uysal M, Erdogan G. Isolated uterine metastasis of invasive ductal carcinoma. Case Rep Oncol Med. 2013;2013:793418.

 

  1. Arslan D, Gündüz S, Tural D, Uysal M, Tatlı AM, Bassorgun CI, Elpek GÖ, Coskun HS, Bozcuk HS, Savas B. Inflammatory myofibroblastic tumor: a rarely seen submucosal lesion of the stomach. Case Rep Oncol Med. 2013;2013:328108.

 

  1. Tural D, Selçukbiricik F, Günver F, Karısmaz A, Serdengecti S. Facial localization of malignant chondroid syringoma: a rare case report. Case reports in oncological medicine. 2013;2013:907980.

 

  1. Tural D, Selçukbiricik F, Erçalıskan A, Inanç B, Günver F, Büyükünal E. Metachronous rectum metastases from gastric adenocarcinoma: a case report. Case reports in medicine.2012;2012:726841.

 

  1. Tural D, Akar E, Oztürk T, Turna H, Serdengeçti S. Malignant clinical presentation of a benign granular cell tumor of breast in a patient with previously treated contralateral invasive ductal carcinoma. Case Rep Oncol Med. 2012;2012:974740.

 

  1. Selcukbiricik F, Tural D, Senel TE, Sarıca A, Soyluk O, Serdengecti S. Bilateral Ischemic Optic Neuropathy Developed under Interferon Therapy. Case Rep Ophthalmol Med. 2012;2012:102739

 

  1. Selcukbiricik F, Tural D, Senel ET, Dervisoglu S, Serdengecti S. Gastric carcinoma with osteoblastic differentiation. Int J Surg Case Rep. 2012;3:516-9.

 

  1. Selcukbiricik F, Tural D, Ozturk MA, Dervisoglu S, Sager S, Hız M, Mandel NM. Gastrointestinal stromal tumor of the rectum with scapular metastasis: a case report.  J Med Case Rep. 2012;6:145.

 

 

  1. Selcukbiricik F, Tural D, Bay A, Sahingoz G, Ilvan S, Mandel NM. A malignant mass in the breast is not always breast cancer. Case Rep Oncol. 2011;4:521-5.

 

  1. Papila B, Yildiz O, Tural D, Delil S, Hasiloglu ZI, Ayan F, Papila C. Wernicke’s Encephalopathy in Colon Cancer. Case Rep Oncol. 2010;3:362-7.

 

 

  1. Selcukbiricik F, Tural D, Esatoglu N, Kocak S, Mandel NM. A very rare adult case with neuroblastoma. Case Rep Oncol. 2011;4:481-6.

 

  1. Selcukbiricik F, Bilici A, Tural D, Erdamar S, Soyluk O, Buyukunal E, Demirelli F, Serdengecti S. Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer?. Tumour Biol. 2013;34:2233-9.

 

 

  1. Selcukbiricik F, Erdamar S, Ozkurt CU, Molinas Mandel N, Demirelli F, Ozguroglu M, Tural D, Buyukunal E, Serdengecti S.The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer. J BUON. 2013 ;18:116-23.

 

  1. Selcukbiricik F, Yalçın S, Tural D, Erdamar S, Demir G, Dogusoy G, Mandel NM. Gastrointestinal stromal tumors in Turkey: experiences from 3 centers. 2013;36:18-24

 

  1. Tural D, Selcukbiricik F, Sager S, Akar E, Yildiz O, Serdengecti SH.PET-CT changes the management and improves outcome in patients with recurrent colorectal cancer. J Cancer Res Ther. 2014;10:121-6.

 

  1. Arslan D, Bozcuk H, Gunduz S, Tural D, Tattli AM, Uysal M, Goksu SS, Bassorgun CI, Koral L, Coskun HS, Ozdogan M, Savas B. Survival Results and Prognostic Factors in T4 N0-3 Non-small Cell Lung Cancer Patients According to the AJCC 7th Edition Staging System. Asian Pac J Cancer Prev. 2014;15:2465-72

 

43.   Tural D, Yuce D, Kilickap S. Mortality in prostate cancer and use of statins.    J Clin Oncol. 2014;32:2274.

 

  1. Arslan D, Gündüz S, Avci F, Merdin A, Tatli AM, Uysal M, Tural D ,Başsorgun CI, Savaş B. Pilomatrix carcinoma of the scalp with pulmonary metastasis: A case report of a complete response to oral endoxan and etoposide. Oncol Lett. 2014;7:1959-1961.

 

 

45.   Tural D, Akar E, Mutlu H, Kilickap S. P95 HER2 fragments and breast cancer outcome. Expert Rev Anticancer Ther. 2014 ;14:1089-96.

46.   Arslan D, Merdin A, Tural D, Temizel M, Akın O, Gündüz S, Tatlı AM, Avcı F, Uysal M. The effect of autoimmunity on the development time of microvascular complications in patients with type 1 diabetes mellitus. Med Sci Monit. 2014 ;20:1176-9.

 

  1. Kivrak Salim D, Mutlu H, Karakurt Eryilmaz M, Yalçin Musri F, Tural D, Coşkun HS. Metronomic maintenance chemotherapy in patients presenting with paraneoplastic autoimmune hepatitis with recurrent thymic carcinoma. J Oncol Pharm Pract. 2014 Sep 16. [Epub ahead of print]

 

  1. Eryilmaz MK, Mutlu H, Salim DK, Musri FY, Tural D, Coskun HS. The neutrophil to lymphocyte ratio has a high negative predictive value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. Asian Pac J Cancer Prev. 2014;15(18):7737-40.

 

  1. Oksüz DC, Tural D, Dincbas FÖ, Dervisoglu S, Turna H, Hiz M, Kantarci F, Ceylaner B, Koca S, Mandel NM. Non-metastatic Ewing’s sarcoma family of tumors of bone in adolescents and adults: prognostic factors and clinical outcome-single institution results. 2014; 100 :452-8.

 

  1. Tural D, Akar E, Öztürk MA, Yıldız Ö, Turna H, Serdengeçti S. Severe liver dysfunction and safe use of 5-fluorouracil leucovorin and oxaliplatin in one patient with metastatic colorectal carcinoma. J Cancer Res Ther. 2014 Jul-Sep;10(3):745-8. doi: 10.4103/0973-1482.136034

 

  1. Arslan D, Koca T, Akar E, Tural D, Ozdogan M. Cancer pain prevalence and its management. Asian Pac J Cancer Prev. 2014;15(20):8557-62.

 

  1. Salim DK, Mutlu H, Eryilmaz MK, Musri FY, Tural D, Gunduz S, Coskun HS. Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors. Asian Pac J Cancer Prev. 2014;15(21):9379-83.

 

 

  1. Musri FY, Mutlu H, Kıvrak Salim D, Karakurt Eryılmaz M, Ünal B, Tural D, Şenol Coşkun H. Sorafenib-induced severe urticaria in a patient with hepatocellular cancer. J Oncol Pharm Pract. 2015 Jan 6. pii: 1078155214565126. [Epub ahead of print]

 

  1. Tural D, Kilickap S. Mortality in colorectal cancer and use of statins. J Clin Oncol. 2015 Mar 1;33(7):810. doi: 10.1200/ JCO.2014.58.7592.

 

  1. Tural D, Kilickap S. First-line crizotinib in ALK-positive lung cancer. N Engl J Med. 2015 Feb 19;372:781.

 

 

 

  1. Eryılmaz MK, Mutlu H, Salim DK, Musri FY, Tural D, Başsorgun I, Coşkun HŞ. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy. J Oncol Pharm Pract. 2016 Jun;22:533-6.

 

  1. Mutlu H, Arslan D, Gündüz S, Tural D, Büyükçelik A, Cihan YB, Aslan T, Bozcuk H, Coşkun HS. The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy. 2014;60(2):107-11.

 

 

 

  1. Ozturk MA, Dane F, Karagoz S, Tural D, Selcukbiricik F, Demirelli F, Buyukunal E,                          Ozguroglu M, Turna H, Erdamar S, Celikel CA, Bozkurtlar EB, Yumuk PF, Mandel NM, Turhal NS, Serdengecti S.  Is perineural invasion (PN) a determinant of disease free survival in early stage colorectal cancer? 2015 Jan-Feb;62(137):59-64

 

  1. Arslan D, Tural D, Koca T, Tastekin D, Kaymak Cerkesli A, Basaran H, Gunduz S, Murat Tatli A, Sezgin Goksu S, Uysal M, Kargi A, Kargi B, Koral L, Ibrahim Bassorgun C, Unal D, Mutlu H, Senol Coskun H, Ozdogan M, Bozcuk H. Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer. J BUON. 2015 Mar-Apr;20(2):573-9.

 

 

  1. Salim DK, Mutlu H, Eryilmaz MK, Salim O, Musri FY, Tural D, Gündüz Ş, Coşkun HŞ. Neutrophil to lymphocyte ratio is an independent prognostic factor in patients with recurrent or metastatic head and neck squamous cell cancer. Mol Clin Oncol. 2015 Jul;3(4):839-842.

 

 

 

  1. Tural D, Kivrak Salim D, Mutlu H, Erkilic M, Gunduz S, Karakurt M, Musri F, Tuna S, Boz A, Aydin F, Karayalcin B, Bozcuk H, Senol Coskun H. Is there any relation between PET-CT SUVmax value and prognostic factors in locally advanced breast cancer?J BUON. 2015 Sep-Oct;20(5):1282-6.

 

  1. Kocoglu H, Velibeyoglu FM, Karaca M, Tural D. Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer. World J Gastrointest Oncol. 2016 Jan 15;8(1):1-7. doi: 10.4251/wjgo.v8.i1.1. Review.

 

 

  1. Kocoglu H, Tural D. About the article “Hepatic steatosis is associated with higher incidence of liver metastasis in patients with metastatic breast cancer; an observational clinical study” by Duran et al. J BUON. 2016 Jan-Feb;21(1):284.
  2. Kocoglu H, Tural D. About the article: “Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study” by Abali et al. J BUON. 2016 Jan-Feb;21(1):285-6.

 

  1. Molinas Mandel N, Selcukbiricik M, Kanitez M, Yalcin S, Tural D, Erdamar S, Dogusoy G, Demir G. Clinical and pathological characteristics and their effect on survival in elderly patients with gastrointestinal stromal tumors. J BUON. 2016 Mar-Apr;21(2):360-5.

 

 

  1. Kocoglu H, Dogan H, Oguz B, Ocak Serin S, Okuturlar Y, Gunaldi M, Erismis B, Ozdemir B, Tural D, Hursitoglu M, Harmankaya O, Kumbasar A. Comparison of Survival Rates, Tumor Stages, and Localization in between Obese and Nonobese Patients with Gastric Cancer.

Gastroenterol Res Pract. 2016;2016:9382750. doi: 10.1155/2016/9382750. Epub 2016 Jun 21

 

  1. Kocoglu H, Karaca M, Turkay R, Tural D. Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion. J BUON. 2016 May-Jun;21(3):754-5.

 

  1. Cil I, Zirtiloglu A, Saydam N, Tural D. Complete response to crizotinib in a patient with adenocarcinoma of the lung cancer harboring c- MET amplification. J BUON. 2017 Jan-Feb;22(1):279-280. No abstract available.

 

  1. Zirtiloglu A, Cil I, Mehmet Velibeyoglu F, Tural D. What are the optimal treatment modalities according to age group in gastric cancer patients? J BUON. 2017 Mar-Apr;22(2):312-319.

 

  1. Cil I, Zirtiloglu A, Velibeyoglu MF, Tural D .What is the optimal treatment of metastatic hepatocellular carcinoma after complete resection; case presentation of ovarian metastasis. J BUON. 2017 Mar-Apr;22(2):557-558. No abstract available.

 

  1. Zirtiloglu A, Cil I, Tural D. Does EGFR targeted therapy change the natural history of EGFR mutant status? J BUON. 2017 Mar-Apr;22(2):560-561. No abstract available.

 

  1. Yildiz I, Bilici A, Karadurmuş N, Ozer L, Tural D, Kaplan MA, Akman T, Bayoglu IV, Uysal M, Yildiz Y, Tanriverdi Ö, Yazici O, Sürmeli Z, Turhal NS, Bavbek S, Selçukbiricik F, Koca D, Basaran M.

Prognostic Factors for Survival in Metastatic Renal Cell Carcinoma Patients with Brain  Metastases Receiving Targeted Therapy. Tumori. 2017 Jul 1:tj5000635. doi: 10.5301/tj.5000635.

 

 

  1. Karaca M, Tural D, Kocoglu H, Selcukbiricik F, Bilgetekin I, Özet A.

Adjuvant chemotherapy for gastric cancer in elderly patients has same benefits as in younger patients. J Cancer Res Ther. 2018 Apr-Jun;14(3):593-596. doi: 10.4103/0973-1482.172588.

 

73.Karaca M, Kocoglu H, Bilgetekin I, Ozet A, Sahinli H, Demir H, Kankoc A, Tural D, Yucel OK.

Ventricular bigeminal rhythm associated with trastuzumab: A potential cardiac side effect.

J Cancer Res Ther. 2018 Jun;14(Supplement):S536-S537. doi: 10.4103/0973-1482.183557.

 

74.Dulgar O, Cil I, Zirtiloglu A, Tural D. Long-lasting response with polycythemia to third-line axitinib treatment in metastatic renal cell carcinoma: Very rare case presentation.

J Oncol Pharm Pract. 2018 Jul 30:1078155218790342

 

  1. Kocoglu H, Karaca M, Tural D, Hocaoglu E, Okuturlar Y, Fetullahoglu Z, Gunaldi M, Ciftci R, Tuna S, Yuce OK, Ozet G, Ozet A, Benekli M. Hepatitis B and C rates are significantly increased in certain solid tumors: A large retrospective study. J Cancer Res Ther. 2018 Sep;14(Supplement):S774-S778. doi: 10.4103/0973-1482

 

  1. Karaca M, Tural D, Akar E, Çil İ, Bayrak S, Ozet G, Yucel OK, Hocaoglu E, Ozet A.Hepatitis B Reactivation Rate Is Higher Undergoing Some Cytotoxic Chemotherapy in Patients with Solid Tumors: A Large Retrospective Study. Chemotherapy. 2018;63(5):247-252. doi: 10.1159/000489789. Epub 2018 Nov

 

Yurt dışı kongrelerde  sunulmuş  bildiriler.

B1. How does (18)f-FDG PET-CT scan affect clinical judgment and change treatment decisions in patients with epithelial ovarian cancer?

Selcukbiricik, F,  Ozguroglu, M, Ozturk, MA , Ozgur, N, Turna, H,  Tural D, Hallac, M, Demirkiran, F, Arvas, M,  Mandel, NM. J Clin Oncol. 2010; 28,15, suppl; abstr 5053)(ASCO 2010)

 

B2. THE EFFECTS OF PATIENT AND TUMOR CHARECTERISTICS AND TREATMENT MODALITIES ON PROGNOSIS OF PATIENTS WITH UVEAL MELANOMA. Tural D, Ozguroglu, M, Turna, H, Selcukbiricik, F, Ozturk, MA, Sevinc, M , Demirkesen, C, Sarici, A Pazarli, H, Serdengecti, S. ANNALS OF ONCOLOGY.2010; 21, 406( Abstr:1337P)(ESMO 2010)

 

B3. IMPORTANCE OF PERINEURAL INVASION IN EARLY STAGE COLORECTAL CANCER

Ozturk, MA, Karagoz, S ,Tural D, Selcukbiricik, F, Yildiz, O, Turna, H, Buyukunal, E, Mandel, NM Erdamar, S, Serdengecti.  ANNALS OF ONCOLOGY. 2010;21, 208-9( Abstr:647P) (ESMO 2010).

 

B4. INCREASING ROLE OF METASTASECTOMY IN METASTATIC BREAST CANCER PATIENTS: WHO BENEFITS MORE . Selcukbiricik, F, Ozguroglu, M, Ozturk, M. A., Turna, H, Tural D, Yildiz, O, Demirelli, F, Serdengecti, S. ANNALS OF ONCOLOGY. 2010 ;21, 111(Abstr:325P)(ESMO 2010)

 

B5. Role of FDG-PET/CT in the Evaluation of Bone Marrow Involvement of Solid Tumours .Yildiz, O, Selcukbiricik, F, Tural D, Turna, H,(Mandel, N. M, Ekmekcioglu, O, Halac, M, Serdengecti, S. EUROPEAN JOURNAL OF CANCER.2011; 47, 210-11(Abstr: 2104)(ESMO 2011)

 

B6. Tumour Characteristics Determining Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer . Turna, Z. Savas, Ozturk, M. A, Tural D, Biricik, F. S, Yildiz, O, Ozguroglu, M. A, Demirelli, F, Mandel, N. M, Buyukunal, E, Serdengecti, S. EUROPEAN JOURNAL OF CANCER. 2011; 47, 344(Abstr:5046)(ESMO 2011)

 

B7. KRas and Braf: Is a Predictor in Metastatic Colorectal Cancer Patients for Bevacizumab?

Selcukbiricik, F, Yildiz, O, Tural D, Ozturk, M. A, Demir, G, Ozguroglu, M, Erdamar, S, Buyukunal, E, Mandel, N. M, Serdengecti, S. EUROPEAN JOURNAL OF CANCER.2011; 47, 397(Abstr: S397)(ESMO 2011)

 

B8. Thromboembolic complications in cancer patients. Yenidunya, Gulsah, Turna, Hande,  Ozturk, Mehmet Akif, Tural, Deniz, Selcukbiricik, Fatih, Yildiz, Ozcan, Ozguroglu, Mustafa, Demirelli, Fuat, Buyukunal, Evin, Serdengecti, Suheyla. JOURNAL OF CLINICAL ONCOLOGY.2012;30( Abstr: e21143).(ASCO 2012)

 

B9. Prognostic significance of the recurrence pattern and risk factors for recurrence in patients with proximal gastric cancer. Bilici, A , Selcukbiricik, F, Ustaalioglu, BBO, Tural D,  Mesut S,  Gumus, M , Serdengecti, S. JOURNAL OF CLINICAL ONCOLOGY 2013;31(Abstr: e15117 )(ASCO 2013)

 

B10. Clinical significance of p95HER2 Overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Tural, D, Demirelli, F, Serdengecti, S, Ozturk, T, Ilvan, S, Turna, H, Ozguroglu, M, Buyukunal, E. EUROPEAN JOURNAL OF CANCER. 2013; 49,420 (Abstr:1914)(ESMO 2013)

 

B11. ER/PR/HER2 receptor discordance between primary tumors and corresponding axillary metastases in curatively resected node positive breast cancer patients . Ozturk, M, Turna, H, Aydin, O, Tural D, Demirelli, F, Ozguroglu, M, Buyukunal, E, Ilvan, S, Serdengecti, S. EUROPEAN JOURNAL OF CANCER. 2013;49,436(Abstr:1966)(ESMO 2013).

 

B12.Clinical, pathological characteristics and the effect on survival in elderly patients with gastrointestinal stromal tumours . Mandel, N. M, Selcukbiricik, F, Demir, G, Dogusoy, G, Erdamar, S, Tural D, Yalcin, S. EUROPEAN JOURNAL OF CANCER.2013;49,593 (Abstr: 2516)(ESMO 2013)

 

 

Yurt içi kongrelerde  sunulmuş bildiriler.

E1. EPİTELYAL OVER KANSERİ OLAN HASTALARDA 18F-FDG PET-BT KLİNİK DEĞERLENDİRME VE TEDAVİ KARARIRINI NASIL ETKİLER. Fatih Selçukbiricik, Mehmet Akif Öztürk, Musatafa Özgüroğlu, Hande Turna, Deniz Tural, Metin Halaç, Fuat Demirkıran, Macit Avras, Nil Molinas Mandel. Sayfa 6,(P-8), III. Tıbbi Onkoloji Kongresi, 24-28 Mart 2010, Antalya.

E2. KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİNDE SOLİTER ORGAN METASTEKTOMİLERİNİN SINIRI NEDİR? OLGU SUNUMU. S.Nihal Esatoğlu, Fatih Selçukbiricik, Mehmet Akif Öztürk, D.Sila Karagöz, Deniz Tural, İsmail Hamzaoğlu, Semih Halezeroğlu, Mustafa Özgüroğlu Sayfa 32,(P-9), III. Tıbbi Onkoloji Kongresi , 24-28 Mart 2010, Antalya.

E3. KLİNİK SEMPTOMLAR BİR TANIYI NASIL DEĞİŞTİREBİLİR? OLGU SUNUMU. S.Nihal Esatoğlu,  Hande Turna, Fatih Selçukbiricik, Mehmet Akif Öztürk, Deniz Tural, Evin Büyükünal. Sayfa 52,(P-050), III. Tıbbi Onkoloji Kongresi, 24-28 Mart 2010, Antalya.

E4. OLFAKTOR NÖROBLASTOMA: CERRAHPAŞA TIP FAKÜLTESİ DENEYİMİ. Deniz Tural, M.Akif Öztürk, Fatih Selçukbiricik, M.Sami İslamoğlu, Yıldız Keleş, Büge Öz, Ömer Uzel, Gökhan Demir, Fuat Demireli, Nil Molinas Mandel.  Sayfa 55,(P-056), III. Tıbbi Onkoloji Kongresi, 24-28 Mart 2010, Antalya.

E5 SADECE İMMÜNHİSTOKİMYASAL SONUÇLARIYLA TRANSTUSUMAB BAŞLANMALI MIDIR? MUHTAMEL BEDELLER ÜZERİNE BİR FİKİR FIRTINASI! Mehmet Akif Öztürk, Mustafa Özgüroğlu, Fatih Selçukbiricik, Hande Turna, Deniz Tural, Zerin Calay, Şennur İlvan, Nil Molinas Mandel, Fuat Demireli, Evin Büyükünal, Süheyla Serdengeçti. Sayfa 72,(P-095), III. Tıbbi Onkoloji Kongresi, 24-28 Mart 2010, Antalya.

E6. SİGMOİD KOLONUN NADİR BİR TÜMÖRÜ: PRİMER MALİNG FİBROZ HİSTİOSİTOMU. Abdulvahap Doğan, Fatih Selçukbiricik, M. Akif Öztürk,  Sinem Koçak, Hande Turna, Deniz Tural, Mustafa Özgüroğlu. Sayfa 99,(P-156), III. Tıbbi Onkoloji Kongresi, 24-28 Mart 2010, Antalya.

E7. PRİMERİ BİLİNMEYEN KEMİK İLİĞİ METASTAZI, GERÇEK TANI KAÇ YIL SONRA KONABİLİR. Hande Turna, Nurgül Özgür, Eren İmre, Fatih Selçukbiricik, Mehmet Akif Öztürk, Deniz Tural, Nüket Tüzüner, Sergülen Dervişoğlu, Nil Molinas Mandel. Sayfa 102,(P-161), III. Tıbbi Onkoloji Kongresi, 24-28 Mart 2010, Antalya.

E8. İLK PREZENTASYONU GLİOBLASTOM OLAN TURCOT SENDROMU. Deniz Tural, M. Sami İslamoğlu, M. Akif Öztürk, Fatih Selçukbiricik, Hande Turna, Mustafa Özgüroğlu. Sayfa 108-9,(P-175), III. Tıbbi Onkoloji Kongresi, 24-28 Mart 2010, Antalya.

E9. BÖBREĞİN NADİR GÖRÜLEN BİR TÜMÖRÜ: SİNOVİYAL SARKOM. Eren İmre, Nurgül Özgür, Fatih Selçukbiricik, Mehmet Akif Öztrük, Deniz Tural, Hande Turna, Mustafa Özgüroğlu. Sayfa 126,(P-212), III. Tıbbi Onkoloji Kongresi, 24-28 Mart 2010, Antalya.

E10. LİPOMU TAKLİT EDEN ATİPİK LENFOMA NÜKSÜ. Sinem Koçak, Fatih Selçukbiricik, Mehmet Akif Öztrük, Berat Oyur, Abdülvahap Doğan, Deniz Tural, Hande Turna, Mustafa Özgüroğlu. Sayfa 136,(P-231), Tıbbi Onkoloji Kongresi, 24-28 Mart 210, Antalya.

E11. KRAS VE BRAF: Metastatik Kolorektal Kanserli Hastalarda Bevacizumab İcin Bir Prediktor mu? Fatih Selçuk Biricik, Mehmet Akif Öztürk, Deniz Tural, Özcan Yıldız, Hande Turna, Gökhan Demir, Sibel Erdamar, Nil Molinas Mandel. Sayfa 21,(P-S11),  19.ULUSAL KANSER KONGRESİ, 20-24 Nisan 2011, Antalya.

 

E12. Adolesan ve Erişkin Non-Metastatik Kemik Yerleşimli Ewing/PNET Tumorlerinde Multidisipliner Tedavi Sonucları-Cerrahpaşa Deneyimi. Didem Colpan Oksuz, Deniz Tural, Fazilet Oner Dincbaş, Fatih Kantarcı, Hande Turna, BeyhanCeylaner, Sergulen Dervişoğlu, Murat Hız, Sedat Koca, Nil Molinas Mandel. Sayfa 62,(P-S42), 19.ULUSAL KANSER KONGRESİ, 20-24 Nisan 2011, Antalya.

 

E13. Solid Tumorlu Hastalarda Kemik İliği Metastazlarının Değerlendirilmesinde

FDG-PET/BT’nin Yeri. Özcan Yıldız, Fatih Selçuk Biricik, Deniz Tural, Hande Turna, Nil Molinas Mandel, Özgül Ekmekçioğlu, Metin Halaç, Süheyla Serdengeçti. Sayfa 282,(P-S168), 19.ULUSAL KANSER KONGRESİ, 20-24 Nisan 2011, Antalya.

 

E14.Metastatik Kolon Kanseri İle İlişkili Wernicke Ensefalopatisi Olgusu. Berrin Papila, Özcan Yıldız, Deniz Tural, Şakir Delil, Zehra Işık Hasıloğlu, Fadıl Ayan1, Çiğdem Papila. Sayfa 547,(P-S418), 19.ULUSAL KANSER KONGRESİ, 20-24 Nisan 2011, Antalya.

 

E 15.Skapulaya Metastaz Yapmış Bir Rektum Gastrointestinal Stromal Tümör.

Fatih Selçuk Biricik, Akif Öztürk, Deniz Tural, Murat Hız, Sergülen Dervişoğlu, Nil Molinas Mande. . Sayfa 555, (P-P426), 19.ULUSAL KANSER KONGRESİ, 20-24 Nisan 2011, Antalya.

 

E16. Lokal İleri Meme Kanserinde Neoadjuvan Kemoterapi Sonuçları

Hande Turna, Mehmet Akif Öztürk, Deniz Turhal, Fatih Selçuk Biricik, Özcan Yıldız, Mustafa

Özgüroğlu, Fuat Demirelli, Nil Mandel, Evin Büyükünal, Süheyla Serdengeçti. Sayfa 410, (P-P290), 19.ULUSAL KANSER KONGRESİ, 20-24 Nisan 2011, Antalya.

 

E17. KOLOREKTAL KANSERDE KRAS/BRAF MUTASYON STATUSU VE KRAS KODON 13 MUTASYONUN ÖNEMİ. Sibel Erdamar, Deniz Tural, Fatih Selçukbiricik, Esra Şimşir, Nil Molinas. Sayfa 11-12,(P-S023), 20.ULUSAL KANSER KONGRESİ, 19-23 Nisan 2013, Antalya.

E18.MİDE KANSERİNDE PRİMER TÜMÖR İLE METASTATİK LENF NODUNUN ERBB2 EKSPRESYONU AÇISINDAN İNCELENMESİ. Fatih Selçukbiricik, Sibel Erdamar, Fuat Demireli, Deniz Tural, Evin Büyükünal, Süheyla Serdengeçti. Sayfa 13,(P-S013), 20.ULUSAL KANSER KONGRESİ, 19-23 Nisan 2013, Antalya

E19. MİDE KARSİNOMUNDA KLİNİKOPATOLOJİK ÖZELİKLER VE HİSTOPATOLOJİK ALT TİPLERİNİN PROGNOSTİK ÖNEMİ CERRAHPAŞ TIP FAKÜLTESİ SERİSİ(714 OLGU). Sibel Erdamar, Burak Mengen, Çiğdem Oba, Beril Tülü, Emre Özmen, Deniz Tural, Fatih Selçukbiricik, Ahmet Dirican. Sayfa 123,(P-148), 20.ULUSAL KANSER KONGRESİ, 19-23 Nisan 2013, Antalya

E20.  KÜRATİF CERRAHİ SONRASI NÜKS GELİŞMİŞ PROKSİMAL MİDE KANSERLİ HASTALARDA NÜKS PATERLERİNİN PROGNOSTİK ÖNEMİ VE NÜKS GELİŞİMİNE ETKİ EDEN RİSK FAKTÖRLERİNİN DEĞERLENDİRLMESİ. Ahmet Bilici, Fatih Selçukbiricik, Bala Başak Öven, Deniz Tural, Mesut Şeker, Mahmut Gümüş, Süheyla Serdengeçti. Sayfa 130-1,(P-161), 20.ULUSAL KANSER KONGRESİ, 19-23 Nisan 2013, Antalya

E21. EKSTRASKELETAL MİKSOİD KONDROSARKOM: OLGU SUNUMU. Berin İnanç, Didem Karaçetin,  Begüm Ökten, Kubilay İnanç, Tülin Kılıçarsaln Öztürk, Deniz Tural… Sayfa 284-1,(P-502), 20.ULUSAL KANSER KONGRESİ, 19-23 Nisan 2013, Antalya

E22.METASTATİK BERRAK HUCRELİ DIŞI KANSERDE SUNİTİNİB TEDAVİSİNİN ETKİNLİĞİ VE TOKSİSİTESİ: COK MERKEZLİ RETROSPEKTİF TOG CALIŞMASI. İBRAHİM YILDIZ, MELTEM EKENEL, TULAY AKMAN, MUHARREM KOCAR, MUKREMİN UYSAL, METİN KANITEZ, UMUT VAROL, DENİZ TURAL, MEHMET ALİ KAPLAN, NİLUFER AVCI, ZEKİ SURMELİ, İSA DEDE, ARİFE ULAŞ, OZAN YAZICI, MERT BAŞARAN. Sayfa 326, (P-S41), V. Tıbbi Onkoloji Kongresi, 19-23 Mart 2014, Antalya.

E23. KANSER HASTALARINDA NUTRİSYON DESTEĞİ: NE BİLİYORUZ, NE YAPIYORUZ? SAADETTİN KILICKAP, DENİZ TURAL, TULAY AKMAN, ERDİNC NAYIR, İBRAHİM PETEKKAYA, YUKSEL URUN, NEYRAN KERTMAN.. Sayfa 379, (P-073), V. Tıbbi Onkoloji Kongresi, 19-23 Mart 2014, Antalya.

E24. LOKAL İLERİ MEME KANSERİNDE PET-CT SUVMAX DEĞERİ İLE PROGNOSTİK

FAKTORLER ARASINDA BİR İLİŞKİ VAR MI? DENİZ TURAL, HAKAN ŞAD BOZCUK,

DERYA KIVRAK SALİM, METİN ERKILIC, ŞEYDA GUNDUZ, ADİL BOZ, MELEK KARAKURT ERYILMAZ, HASAN MUTLU, BİNNUR KARAYALCIN, HASAN ŞENOL COŞKUN. Sayfa 486, (P-241), V. Tıbbi Onkoloji Kongresi, 19-23 Mart 2014, Antalya.

E25. ANTİ-VEGF TKİ VERİLEN BEYİN METASTAZLI RENAL HUCRELİ KANSER OLGULARINDA KLİNİK SONUCLAR VE PROGNOSTİK FAKTORLER: COK MERKEZLİ TOG CALIŞMASI İLK

SONUCLARI. İBRAHİM YILDIZ, MELTEM EKENEL, TULAY AKMAN, IBRAHİM VEDAT BAYOĞLU, DENİZ TURAL, OZAN YAZICI, OZGUR TANRIVERDİ, ZEKİ SURMELİ, UMUT VAROL,

MEHMET ALİ KAPLAN, DOĞAN KOCA, METİN KANITEZ, MERT BASARAN. Sayfa 549, (P-333), V. Tıbbi Onkoloji Kongresi, 19-23 Mart 2014, Antalya.

E26. INTERFERON ALFA 2B SONRASİ ANTİANJİOGENİK HEDEFLİ TEDAVİ

KULLANAN METASTATİK RENAL HUCRELİ KARSİNOM TANILI

HASTALARDA SİTOREDUKTİF NEFREKTOMİ İHTİYACI. HASAN MUTLU, ŞEYDA GUNDUZ, ABDULLAH BUYUKCELİK, OZCAN YILDIZ, MUKREMİN UYSAL, DENİZ TURAL, HAKAN BOZCUK, HASAN ŞENOL COŞKUN. Sayfa 550, (P-335), V. Tıbbi Onkoloji Kongresi, 19-23 Mart 2014, Antalya.

Uluslar arası yazılmış kitap bölümleri

Human Papillomavirus; Makbule Tambas, Musa Altun and Deniz Tural. Chapte 11,  Human Papillomavirus in Head and Neck Cancer

 

Ulusal yazılmış kitap bölümü

Merkez Sinir Sisteminin Neoplastik Hastalıkları. Fatih Selçuk Biricik, Mehmet Akif Öztürk, Deniz Tural, Özcan Yıldız, Hande Turna, Mustafa Özgüroğlu, Didem Çolpan Öksüz, Fazilet Öner Dinçbaş, Ömer Uzel, ali Kafadar, Ahmet Bilici. Nöroloji Temel Kitabı. Editörler: Murat Emre, Gökhan Erkol. Birinci Baskı, Güneş Tıp Kitabevleri, Ankara, 2013, Sayfa: 1263-1287.

 

Aldığı Ödüller

2016 Türk Tıbbî Onkoloji Derneği’nin Belek Antalya’da düzenlediği 6. Türk Tıbbî Onkoloji Kongresi’nde “Neoadjuvan Kemoterapi Sonrası Reseptör Diskordansı ve Hastalıksız Sağkalım Üzerine Etkisi” konulu sözel bildirisi ile “En İyi Sözel Bildiri Ödülü.

2017 Türk Tıbbî Onkoloji Derneği’nin Belek Antalya’da düzenlediği 22 Ulusak Kanser Kongresi’nde” Solid Kanserlerli Hastalarda Hepatit B ve C Sıklığı ve Sitotoksik Kemoterapiye Bağlı Hepatit Reaktivasyon Oranının Saptanması “Poster Bildiri Ödülü.

2018.Türk Tıbbî Onkoloji Derneği’nin Belek Antalya’da düzenlediği 7. Türk Tıbbî Onkoloji Kongresi’nde ” Lokal ileri akciğer kanserinde Tümör Hücrelerinde PD-L1 pozitifliği sağ kalım üzerinde prognostik etkisi vardır “ konulu sözel bildirisi ile En İyi poster Bildiri” Ödülü.

2018.Türk Tıbbî Onkoloji Derneği’nin Belek Antalya’da düzenlediği 7. Türk Tıbbî Onkoloji Kongresi’nde ” Mamografi ile Taramanın Meme Kanseri Sağ kalımı Üzerine Etkinliği Yeni Tedavi Seçenekleri ile Azalıyor “ konulu sözel bildirisi ile En İyi poster Bildiri” Ödülü.

2018.Türk Tıbbî Onkoloji Derneği’nin Belek Antalya’da düzenlediği 7. Türk Tıbbî Onkoloji Kongresi’nde ” Evre IV akciğer kanserinde PD-L1 düzeyinin %50 ve üzeri olması kötü prognostik faktör olarak kullanılabilinir “ konulu sözel bildirisi ile En İyi sözel Bildiri” Ödülü.

  1. Türk Tıbbî Onkoloji Derneği‘nin Belek Antalya’da düzenlediği23 Ulusak Kanser Kongresi’nde“ Radikal Sistektomi Yapılan Mesane Kanserli Hastalarda TIL, MSI ve PD-L1’in Sağkalım Üzerine Etkisi bildirisi ilke En iyi Çalışma ödülü.

Aldığı Sertifikalar

ESMO Examination Certificate  2013

Türk Tıbbi Onkoloji Yeterlilik belgesi 2014

 

Üye Olduğu dernekler

 

  • American Society of Clinical Oncology

 

  • European Society For Medical Oncology

 

  • Turkish Society of Clinical Oncology

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


    Deniz Tural301 Gönderi 9 Yorum

    E-Mail: deniztural@gmail.com

    Bunları da beğenebilirsin Yazarın diğer gönderileri
    Yorum Bırakın

    E-posta hesabınız yayımlanmayacak.